Beacon of hope for XLRP patients on Phase III gene therapy success
Beacon Therapeutics will seek approval for its gene therapy, laruparetigene zovaparvovec (laru-zova), in patients with X-linked retinitis pigmentosa (XLRP) after …
Post
-
-
First patient dosed in Accro Bioscience’s Phase IIb AC-101 study
Accro Bioscience (Accro Bio) has dosed the first patient in its Phase IIb clinical trial assessing AC-101, a selective receptor-interacting …
-
Addressing the global trial enrolment challenge
This October will see experts meet in the biotech hub of Boston to assess the scale and solutions for the …
-
Otsuka reports expanded Phase IIIb results for Simtriyo in adult ADHD
Otsuka Pharmaceutical Development & Commercialisation and Otsuka Pharmaceutical have reported expanded Phase IIIb results for Simtriyo (centanafadine) in adults with …
-
Roche seeking earlier use for Lunsumio in FL on Phase III data
Roche is seeking a label expansion to use Lunsumio (mosunetuzumab) at an earlier stage after it showed benefit in a …
-
Everest acquires Firma’s biometrics and data services unit
Everest Clinical Research has acquired Firma Clinical Research's biometrics and data services business unit, Firma DS, for an undisclosed sum. The …
-
China’s NMPA clears Akeso’s AK158D1 for Phase I trial in solid tumours
Akeso has received clearance from the Center for Drug Evaluation (CDE) under China’s National Medical Products Administration (NMPA) to begin …
-
Podcast: What’s new in pulmonary fibrosis: Insights from ERS 2026
The 2026 European Respiratory Society (ERS) Conference ended recently after providing a platform for emerging research in pulmonary fibrosis, a …
-
Altis Labs’ AI software detected treatment benefit earlier in oncology trial
Altis Labs’ artificial intelligence (AI)-powered imaging endpoint has shown its ability to detect early, notable treatment effects more effectively than …
-
Optimi Health plans Phase III trial of PTSD therapy
Optimi Health is set to initiate a Phase III clinical trial to assess methylenedioxymethamphetamine (MDMA)-assisted therapy to treat individuals living …
-
SpliSense begins Phase IIb SPL84 trial for cystic fibrosis
SpliSense has commenced a Phase IIb clinical trial of its inhaled antisense oligonucleotide therapy, SPL84, in people with cystic fibrosis …
-
Axoltis’ Phase II ALS trial fails; company points to exploratory endpoints
Axoltis Pharma is undertaking additional analysis of its Phase II amyotrophic lateral sclerosis (ALS) trial after it failed to meet …
-
OCT China 2026: China becoming ‘centre of gravity’ in global clinical trial sector
China’s rapid growth in recent years has sent ripples across the pharmaceutical sector. The country has experienced significant growth over the …
-
Syntis Bio announces Phase I/Ib data for SYNT-101 in obesity
Syntis Bio has reported results from the multiple ascending dose (MAD) segment of its Phase I/Ib SYNTIETY-1 trial of SYNT-101, …
-
Arrowhead reports top-line results in mixed hyperlipidaemia trial
Arrowhead Pharmaceuticals has reported interim top-line results from an ongoing Phase I/IIa clinical trial investigating ARO-DIMER-PA to treat mixed hyperlipidaemia. ARO-DIMER-PA …
